Evidence map›Paper›PMID 42410179›Full record

ArticleScientific reports2026

Comparison of capillary microsampling and venous blood for multi-pathogen serosurveillance.

Rose Ombati, Makobu Kimani, Donald Akech, Bernadette Kutima, Antipa K Sigilai, Boniface Karia, Victor Osoti, Angela Karani, Abdhalah Ziraba, Godfrey Bigogo and 5 more

Abstract read
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Rose OmbatiKEMRI-Wellcome Trust Research Programme, Kilifi, Kenya.
Makobu KimaniKEMRI-Wellcome Trust Research Programme, Kilifi, Kenya.
Donald AkechKEMRI-Wellcome Trust Research Programme, Kilifi, Kenya.
Bernadette KutimaKEMRI-Wellcome Trust Research Programme, Kilifi, Kenya.
Antipa K SigilaiKEMRI-Wellcome Trust Research Programme, Kilifi, Kenya.
Boniface KariaKEMRI-Wellcome Trust Research Programme, Kilifi, Kenya.
Victor OsotiKEMRI-Wellcome Trust Research Programme, Kilifi, Kenya.
Angela KaraniKEMRI-Wellcome Trust Research Programme, Kilifi, Kenya.
Abdhalah ZirabaAfrican Population and Health Research Center, Nairobi, Kenya.
Godfrey BigogoKEMRI Centre for Global Health Research, Kisumu, Kenya.
Patrick MunywokiDivision for Global Health Protection, Center for Global Health, US Centers of Disease Control and Prevention, Nairobi, Kenya.
J Anthony G ScottKEMRI-Wellcome Trust Research Programme, Kilifi, Kenya.
Ambrose AgweyuKEMRI-Wellcome Trust Research Programme, Kilifi, Kenya.
E Wangeci KaguciaKEMRI-Wellcome Trust Research Programme, Kilifi, Kenya.
James NyagwangeKEMRI-Wellcome Trust Research Programme, Kilifi, Kenya. JNyagwange@kemri-wellcome.org.ORCID https://orcid.org/0000-0001-5430-6011

Funding

Bill & Melinda Gates Foundation INV-039626Gates Foundation INV-039626Wellcome Trust
6 · The paper itself

Abstract

Serosurveillance for vaccine-preventable diseases (VPDs) can inform public health strategies by identifying gaps in immunization programs. However, venous blood sampling, though reliable and sensitive for serosurveillance, presents logistical challenges in resource-limited settings. Capillary microsampling using dried blood spots (DBS) offers a simpler, less invasive alternative that reduces cold-chain and personnel requirements. This study evaluated the performance and stability of DBS collected on filter paper and Mitra microsamplers compared with venous plasma. IgG antibody levels against diphtheria, tetanus, pertussis, measles, mumps, rubella, and varicella were quantified using a validated fluorescent bead-based multiplex immunoassay. At baseline, strong agreement was observed between DBS and plasma, with ≥ 93% of observations within the 95% limits of agreement. Sensitivity was high (≥ 95.8%) for all pathogens except pertussis (72.2-77.8%). For DBS stored at - 20 °C with desiccants, agreement remained high at 90 days, with gradual declines observed beyond one year. At room temperature, IgG levels declined, with sensitivity ≥ 91.2% at 7 and 30 days but dropping below 90% by 90 days for several analytes. Beyond one year, IgG recovery was minimal, with sensitivity < 50% for most pathogens. These findings support DBS utility for VPD serosurveillance, with stability up to 90 days at - 20 °C and 30 days at room temperature.

Indexed as

Antibody stabilityDBSIgG antibodiesMultiplex immunoassaySerosurveillanceVaccine-preventable diseases

Identifiers

PMID42410179
PMCPMC13638452

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.